simple website templates

superior data technologies for digital health

Human health R&D has become inherently rich in data, including extensive clinical phenotyping, large scale molecular profiling, improved treatment effect monitoring, as well as assessment of external and environmental factors. Alongside, innovative data management and analytics have become pivotal: converting complex data spaces into relevant insight and actionable results.

emergentec combines expertise in medical research and computer science, and establishes superior data technologies geared toward enabling precision medicine. We develop operational environment-ready software and integrated analytics workflows for digital health R&D, pursuing proprietary technology development as well as collaborative initiatives.

our lead platform OPAi - health

Linking Observation (molecular & clinical characteristics) retrieved from Phenotypes (patients) and underlying (molecular) Architecture in an  ntelligent fashion: Our OPAi  proprietary approach, realized as hybrid numerical/symbolic AI, leverages on big data while enforcing determinism and causality in strict categorical models. OPAi  input uses time series from patient phenotyping, output offers personalized prognosis and treatment response assessment.

OPAi  establishes predictive models using retrospective data, and continuously learns as new data are added. Next to improved accuracy the models allow mechanistic interpretation of pathophysiology in the realm of treatment effect, being of particular relevance in health applications.

our offering

✪  We consult in design & implementation of data technologies for digital health challenges, covering data management aspects as well as analysis concepts and workflow implementation.
✪  We offer OPAi - health analytics for phenotype cohort segregation/stratification and treatment response assessment.


Conceptual design and implementation (Technology Readiness Level 9) of proprietary technology:

✪ a computational vaccinology platform; licensed to a US-based biotech enterprise

✪ a knowledge graph platform; licensed to various European academic institutions

✪ an image analysis platform; licensed to a US-based knowledge provider

✪ a digital drug R&D platform; licensed to a European biotech enterprise

Custom technology solutions and applications:

✪  Data space configurations, covering from translational research initiatives to clinical studies

✪  Analysis workflows for identification of stratification biomarkers (chronic and acute clinical conditions)

✪  Integrated in-silico/experimental processes for drug positioning/repositioning (chemicals and biologicals)

Selected public references:

✪  Collaborative research initiative: SysKid (link to video)

✪  Models in drug MoA-pathology matching: review (link to article)

✪  OPAi in drug positioning. DC-ren, a H2020 project: 04/2020 press release (as pdf)

✪  OPAi in disease comorbidity. DISCOvERIE, a H2020 project:  02/2020 press release (as pdf)



          emergentec biodevelopment GmbH

          Gersthofer Strasse 29-31

          1180 Vienna, Austria